Soft Tissue Sarcoma
George D. Demetri(Dana-Farber Cancer Institute), Jeffrey D. Wayne(Northwestern University), Thomas F. DeLaney(Massachusetts General Hospital), Marilyn M. Bui, Kristen N. Ganjoo(Stanford Medicine), Katherine A. Thornton(Memorial Sloan Kettering Cancer Center), Robert S. Benjamin(The University of Texas MD Anderson Cancer Center), Scott Antonia(Parker Institute for Cancer Immunotherapy), I. Benjamin Paz, R. Lor Randall(University of California Davis Medical Center), Raymond J. Hutchinson(Children's Hospital of Los Angeles), Raphael E. Pollock(The Ohio State University), Sean V. McGarry(City of Hope), Martin J. Heslin(City of Hope), Richard F. Riedel(Heidelberg University), G. Douglas Letson(Moffitt Cancer Center), Margaret von Mehren(Temple University Health System), Richard J. OʼDonnell(The University of Texas MD Anderson Cancer Center), John M. Kane(Roswell Park Comprehensive Cancer Center), Karen D. Schupak, Ernest U. Conrad, John D. Pfeifer(Washington University in St. Louis), Ephraim S. Casper(Cornell University), Herbert S. Schwartz(Vanderbilt University)
Cited by 167
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k